ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
Investors are showing growing interest in the rapidly expanding structural heart device market, which is expected to witness a compound annual growth rate (CAGR) of 13.5% between 2025 and 2033, acc...
Abbott's Navitor™ TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis
Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at...
Abbott Laboratories Q2 Earnings: Dividends Don't Lie
Abbott's Q2 performance reflects some evenness and the potential headwinds from macroeconomic uncertainties. However, short-term issues like tariffs and drug price control do not fundamentally alte...
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
3 Dividend Growth Stocks That Will Deliver Meaty Returns After 5 Years
Sufficient earnings growth to continually increase dividends at a comfortably low payout ratio that also accommodates expansion capex is an excellent signal for strong upside potential.
Best Dividend Aristocrats For August 2025
Dividend Aristocrats are outperforming SPY in July but still trail year-to-date; select Aristocrats delivered double-digit gains and strong dividend growth. 47 of 69 Aristocrats raised dividends in...
Abbott Laboratories: What's Behind The Q2 Earnings Slump?
ABT, which had been outperforming the healthcare cohort from the S&P 500 and the S&P 500 itself all through this year, has slumped dramatically following yesterday's Q2 earnings. While Q2 sales bea...
Didn't see the recovery in China we were expecting, says Abbott Labs CEO on lowering guidance
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.
Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares.
Abbott Laboratories stock falls even as the company reports second-quarter sales that top expectations.
Countdown to Abbott (ABT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qu...
Abbott Labs: Proactive, Adaptive, Solid
Abbott's proactive leadership and diversified business model help it navigate macro challenges and market volatility effectively. Strong Q1 performance in Nutrition, Medical Devices, and Vascular s...
Best Dividend Kings: June 2025
Dividend Kings have underperformed the S&P 500 year-to-date, but 26 are outperforming SPY in 2025, with 32 posting positive returns. Dividend growth remains healthy, with four recent increases and ...
New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier
Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and repo...
ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?
Abbott gains Health Canada approval for its i-STAT TBI test, enabling rapid bedside concussion detection via whole blood.
Related Companies